Canaccord analyst Kyle Rose downgraded Globus Medical (GMED) to Hold from Buy with an unchanged price target of $75 after the company entered into an all-stock merger transaction with NuVasive (NUVA).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on GMED: